MXPA03007837A - Composiciones para suministrar bisfosfonatos. - Google Patents

Composiciones para suministrar bisfosfonatos.

Info

Publication number
MXPA03007837A
MXPA03007837A MXPA03007837A MXPA03007837A MXPA03007837A MX PA03007837 A MXPA03007837 A MX PA03007837A MX PA03007837 A MXPA03007837 A MX PA03007837A MX PA03007837 A MXPA03007837 A MX PA03007837A MX PA03007837 A MXPA03007837 A MX PA03007837A
Authority
MX
Mexico
Prior art keywords
compositions
bisphosphonates
delivering
delivering bisphosphonates
administration
Prior art date
Application number
MXPA03007837A
Other languages
English (en)
Inventor
Maria A P Boyd
Original Assignee
Emisphere Techonologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Techonologies Inc filed Critical Emisphere Techonologies Inc
Publication of MXPA03007837A publication Critical patent/MXPA03007837A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion proporciona compuestos y composiciones para el suministro de bisfosfonatos. Los metodos de preparacion, administracion y tratamiento son provistos tambien.
MXPA03007837A 2001-03-01 2002-03-01 Composiciones para suministrar bisfosfonatos. MXPA03007837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27267601P 2001-03-01 2001-03-01
PCT/US2002/006295 WO2002070438A2 (en) 2001-03-01 2002-03-01 Compositions for delivering bisphosphonates

Publications (1)

Publication Number Publication Date
MXPA03007837A true MXPA03007837A (es) 2004-03-16

Family

ID=23040792

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007837A MXPA03007837A (es) 2001-03-01 2002-03-01 Composiciones para suministrar bisfosfonatos.

Country Status (14)

Country Link
US (1) US7309698B2 (es)
EP (1) EP1372667B1 (es)
JP (1) JP4354698B2 (es)
KR (1) KR20030083725A (es)
CN (1) CN1492763B (es)
AU (1) AU2002254082B2 (es)
BR (1) BR0207871A (es)
CA (1) CA2438848C (es)
HK (1) HK1062557A1 (es)
MX (1) MXPA03007837A (es)
NZ (1) NZ527157A (es)
RU (1) RU2309945C2 (es)
WO (1) WO2002070438A2 (es)
ZA (1) ZA200305606B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2595697A (en) 1996-03-29 1997-10-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) * 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
AU2002330692A1 (en) * 2001-07-02 2003-01-21 Elan Corporation, Plc. Delivery of a bioactive material
PL371264A1 (en) * 2001-12-21 2005-06-13 The Procter & Gamble Company Method for the treatment of bone disorders
ES2614603T3 (es) * 2002-02-20 2017-06-01 Emisphere Technologies, Inc. Procedimiento de administración de moléculas GLP-1
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
DE60315514T3 (de) * 2002-12-20 2012-04-26 F. Hoffmann-La Roche Ag Hochdosierte ibandronat-formulierung
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
ES2879880T3 (es) * 2004-05-06 2021-11-23 Novo Nordisk North America Operations As Formas polimórficas cristalinas del n-[8-(2-hidroxibenzoil)amino]caprilato monosódico
NZ551196A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
MXPA06013384A (es) 2004-05-19 2007-03-01 Emisphere Tech Inc Formulaciones topicas de cromolin.
MXPA06013295A (es) 2004-05-19 2007-02-22 Emisphere Tech Inc Formulaciones de aciclovir.
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
CN105708787A (zh) * 2004-07-12 2016-06-29 爱密斯菲尔科技公司 用于递送肽yy和pyy激动剂的组合物
WO2006017541A2 (en) 2004-08-03 2006-02-16 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
MX2007008082A (es) 2004-12-29 2007-09-05 Emisphere Tech Inc Formulaciones farmaceuticas de sales de galio.
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
AU2006215300C9 (en) * 2005-02-17 2010-05-06 Hadasit Medical Research Services And Development Ltd. Bisphosphonates for treating endometriosis
WO2007011958A2 (en) 2005-07-15 2007-01-25 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007133944A2 (en) 2006-05-09 2007-11-22 Emisphere Technologies, Inc. Topical administration of acyclovir
WO2008003050A2 (en) 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2681158C (en) 2007-03-13 2018-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
TW200950799A (en) * 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) * 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
JP5985985B2 (ja) 2009-08-03 2016-09-06 エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． 胃腸への影響が減少した即効型ナプロキセン組成物
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物
EP2680861B1 (en) 2011-03-01 2022-05-04 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
EP3413900A1 (en) 2016-02-11 2018-12-19 Nutrition 21, LLC Chromium containing compositions for improving health and fitness
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
AU2595697A (en) 1996-03-29 1997-10-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5776888A (en) * 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE295347T1 (de) * 1998-07-27 2005-05-15 Emisphere Tech Inc Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
EP1163209A4 (en) 1999-02-26 2004-12-29 Emisphere Tech Inc COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
NZ530450A (en) * 1999-11-05 2004-06-25 Emisphere Tech Inc Phenoxy carboxylic acid compounds and compositions for delivering active agents
ES2298168T3 (es) * 1999-12-16 2008-05-16 Emisphere Technologies, Inc. Compuestos y composiciones para suministrar agentes activos.
JP4799794B2 (ja) * 2000-03-21 2011-10-26 エミスフェアー・テクノロジーズ・インク ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
EP1322595B1 (en) * 2000-09-06 2008-05-28 Emisphere Technologies, Inc. (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents

Also Published As

Publication number Publication date
RU2003129165A (ru) 2005-03-27
BR0207871A (pt) 2004-06-22
EP1372667B1 (en) 2014-10-15
WO2002070438A2 (en) 2002-09-12
CN1492763B (zh) 2012-05-23
HK1062557A1 (en) 2004-11-12
CN1492763A (zh) 2004-04-28
EP1372667A2 (en) 2004-01-02
CA2438848A1 (en) 2002-09-12
ZA200305606B (en) 2004-08-25
WO2002070438A3 (en) 2003-04-24
AU2002254082B2 (en) 2007-05-24
KR20030083725A (ko) 2003-10-30
NZ527157A (en) 2005-04-29
JP2004528303A (ja) 2004-09-16
EP1372667A4 (en) 2007-03-14
RU2309945C2 (ru) 2007-11-10
CA2438848C (en) 2011-05-03
US7309698B2 (en) 2007-12-18
JP4354698B2 (ja) 2009-10-28
US20040147484A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
IL153297A0 (en) Compounds and compositions for delivering active agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
PL347671A1 (en) Compounds and compositions for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
HK1036970A1 (en) Compounds and compositions for delivering active agents.
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
WO2005112633A3 (en) Compounds and compositions for delivering active agents
MY129263A (en) Vaccine composition
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
TW200508214A (en) Novel compounds
HK1059395A1 (en) Polymeric micelle compositions
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
AU3492100A (en) Oxadiazole compounds and compositions for delivering active agents
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2002015959A3 (en) Compounds and compositions for delivering active agents
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
WO2002100338A3 (en) Compound and composition for delivering active agents
MXPA03005374A (es) Carbazoles antitumorales.
WO2005062874A3 (en) Compounds and compositions for delivering active agents
MX2008002272A (es) Compuestos de ciclopropilo y composiciones para suministrar agentes activos.

Legal Events

Date Code Title Description
FG Grant or registration